Tech Company Financing Transactions
F2G Funding Round
F2G secured a $60.8 million financing round on 8/13/2020. Backers included Cowen Capital Partners, Advent Life Sciences and Brace Pharma.
Transaction Overview
Company Name
Announced On
8/13/2020
Transaction Type
Venture Equity
Amount
$60,800,000
Round
Undisclosed
Investors
Cowen Capital Partners (Lead Investor) (Timothy Anderson)
Proceeds Purpose
Proceeds from the financing will be used to fund F2G's late-stage clinical programs for their novel antifungal agent olorofim and organisational scale-up in preparation for commercialisation.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Lankro Way Eccles
Manchester, M30 0LX
UK
Manchester, M30 0LX
UK
Phone
Website
Email Address
Overview
F2G is a world leading UK biotech company focused on the discovery and development of novel therapies to treat life threatening invasive fungal infections, with experienced management and board. F2G has discovered and developed a completely new class of antifungal agents called the orotomides.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ian Nicholson
Chief Financial Officer
Ralf Schmid
Chief Medical Officer
Emma Harvey
Chief Medical Officer
John Rex
Chief Operating Officer
Michael Birch
Chief Scientific Officer
Tony Kennedy
Browse more venture capital transactions:
Prev: 8/13/2020: Allergy Amulet venture capital transaction
Next: 8/13/2020: TearClear venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs